Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 15/20 | 1.00 |
| ▸ | TGFB2 | P61812 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.31 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29978401 | 1.00 | TGFBR1 (1.00) | TGFBR1TGFB2CYP2A6IRAK4MAPK14 | |
| SCHEMBL2010521 | 0.92 | TGFBR1 (1.00) | TGFBR1TGFB2MAPK14 | |
| SCHEMBL29977977 | 0.92 | TGFBR1 (1.00) | TGFBR1TGFB2MAPK14 | |
| SCHEMBL15445425 | 0.88 | TGFBR1 (0.78) | TGFBR1TGFB2RECQL | |
| SCHEMBL2009749 | 0.80 | TGFBR1 (1.00) | TGFBR1TGFB2CYP2A6IRAK4 | |
| SCHEMBL29978376 | 0.80 | TGFBR1 (1.00) | TGFBR1TGFB2CYP2A6IRAK4 | |
| SCHEMBL2007716 | 0.72 | TGFBR1 (1.00) | TGFBR1TGFB2CYP2A6MAPK14 | |
| SCHEMBL29978020 | 0.71 | TGFBR1 (1.00) | TGFBR1TGFB2IRAK4MAPK14 | |
| SCHEMBL2011347 | 0.71 | TGFBR1 (1.00) | TGFBR1TGFB2IRAK4MAPK14 | |
| SCHEMBL25942605 | 0.70 | TGFBR1 (0.55) | TGFBR1IRAK4RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9938289-B2 | Therapeutic pyrazolyl thienopyridines | FBM THERAPEUTICS, LLC (US) | 2018-04-10 | — | — | US | claimed |
| US-20160200735-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | THIRONA BIO, INC. | 2016-07-14 | — | — | US | claimed |
| US-9260450-B2 | Therapeutic pyrazolyl thienopyridines | THESAN PHARMACEUTICALS, INC. (US) | 2016-02-16 | — | — | US | claimed |
| US-20150175624-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | THIRONA BIO, INC. | 2015-06-25 | — | — | US | claimed |
| US-20110224251-A1 | Therapeutic Pyrazolyl Thienopyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2011-09-15 | — | — | US | claimed |
| US-20080090861-A1 | Cancer and fibrotic disorders such as scarring prevention; 2-(4-methyl-1-(6-methylpyridin-2-yl)-1H-pyrazol-5-yl)thieno[2,3-c]pyridine for example; activin receptor-like kinase-5 (ALK-5) inhibitors | PFIZER INC. | 2008-04-17 | — | — | US | claimed |
| US-20250134875-A1 | FORMULATIONS OF ALK-5 KINASE INHIBITORS AND USES THEREOF | THIRONA BIO, INC. (US) | 2025-05-01 | — | — | US | disclosed |
| US-20240307363-A1 | METHODS FOR TREATING A PULMONARY DISEASE WITH AN ALK-5 (TGF BETA R1) INHIBITOR | THIRONA BIO, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| EP-4333853-A1 | METHODS FOR TREATING A PULMONARY DISEASE WITH AN ALK-5 (TGF BETA R1) INHIBITOR | Thirona Bio, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-9938289-B2 | Therapeutic pyrazolyl thienopyridines | FBM THERAPEUTICS, LLC (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938289-B2 | Therapeutic pyrazolyl thienopyridines | FBM THERAPEUTICS, LLC (US) | 2018-04-10 | — | — | US | disclosed |
| US-9938289-B2 | Therapeutic pyrazolyl thienopyridines | FBM THERAPEUTICS, LLC (US) | 2018-04-10 | — | — | US | disclosed |
| US-20160200735-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | THIRONA BIO, INC. | 2016-07-14 | — | — | US | disclosed |
| US-7964612-B2 | Therapeutic pyrazolyl thienopyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2074128-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | Pfizer Products Incorporated (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008047198-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | PFIZER PRODUCTS INC. (US) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008047198-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | PFIZER PRODUCTS INC. (US) | 2008-04-24 | — | — | WO | disclosed |
| US-20080090861-A1 | Cancer and fibrotic disorders such as scarring prevention; 2-(4-methyl-1-(6-methylpyridin-2-yl)-1H-pyrazol-5-yl)thieno[2,3-c]pyridine for example; activin receptor-like kinase-5 (ALK-5) inhibitors | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090861-A1 | Cancer and fibrotic disorders such as scarring prevention; 2-(4-methyl-1-(6-methylpyridin-2-yl)-1H-pyrazol-5-yl)thieno[2,3-c]pyridine for example; activin receptor-like kinase-5 (ALK-5) inhibitors | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
| US-20080090861-A1 | Cancer and fibrotic disorders such as scarring prevention; 2-(4-methyl-1-(6-methylpyridin-2-yl)-1H-pyrazol-5-yl)thieno[2,3-c]pyridine for example; activin receptor-like kinase-5 (ALK-5) inhibitors | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200735-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | TGFBR1, SMAD3, TGFBR2 | TGFBR1 1/4885TGFB2 7/4885CYP2A6 1553/4885 |
| US-20250134875-A1 | FORMULATIONS OF ALK-5 KINASE INHIBITORS AND USES THEREOF | ALK, ACVR1, ACVRL1 | TGFBR1 81/4885TGFB2 270/4885CYP2A6 3140/4885 |
| US-20240307363-A1 | METHODS FOR TREATING A PULMONARY DISEASE WITH AN ALK-5 (TGF BETA R1) INHIBITOR | ALK, TGFBR1, TGFBR2 | TGFBR1 2/4885TGFB2 66/4885CYP2A6 4435/4885 |
| US-20110224251-A1 | Therapeutic Pyrazolyl Thienopyridines | TGFBR1, SMAD3, TGFBR2 | TGFBR1 1/4885TGFB2 7/4885CYP2A6 1553/4885 |
| US-20150175624-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | TGFBR1, SMAD3, TGFBR2 | TGFBR1 1/4885TGFB2 7/4885CYP2A6 1553/4885 |
| US-20080090861-A1 | Cancer and fibrotic disorders such as scarring prevention; 2-(4-methyl-1-(6-methylpyridin-2-yl)-1H-pyrazol-5-yl)thieno[2,3-c]pyridine for example; activin receptor-like kinase-5 (ALK-5) inhibitors | ACVR1, TGFBR1, ACVRL1 | TGFBR1 2/4885TGFB2 23/4885CYP2A6 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.